Skip to main content
ACXP
NASDAQ Life Sciences

Acurx Q3 Loss Widens to $2.58M as Going-Concern Doubt Persists on $9.7M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.966
Mkt Cap
$5.337M
52W Low
$0.92
52W High
$7.539
52W Position info
5.0% above low
Off High info
87% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

ACXP is trading near its 52-week low of $0.92 (5.0% above the low) on elevated volume (2.2× avg).

Summary

Acurx posted a $2.58 million Q3 loss and reiterated substantial doubt about its ability to continue as a going concern, with $9.65 million in cash that won't cover 12 months of operations. The company is leaning on its Lincoln Park equity line, selling another 143,787 shares for about $0.2 million after quarter-end.


Key Events · Earnings and Guidance · ACXP

  • Q3 Net Loss Widens to $2.58M

    The net loss for the three months ended September 30, 2026 was $2.58 million, versus $1.99 million a year earlier, and the nine-month loss was $6.52 million.

  • Going Concern Doubt Reiterated

    Management states that $9.7 million of cash at September 30, 2026 will not be sufficient to meet anticipated cash requirements for at least 12 months, raising substantial doubt about the ability to continue as a going concern.

  • R&D Spend Jumps 160%

    Research and development expense rose to $1.12 million in Q3 from $0.43 million, driven by consulting and manufacturing costs for the new recurrent CDI trial program.

  • Equity Line Keeps Funding Operations

    The company sold 2,598,154 ELOC shares for $5.51 million gross in the nine months, plus 143,787 more shares for about $0.2 million through November 12, 2026, bringing cumulative sales to 3,493,338 shares for about $9.6 million.


Analysis · ACXP · Life Sciences

Cash burn is the headline here: Acurx used $5.6 million in operations over the first nine months of 2026 and closed September with $9.65 million, a balance management says will not last 12 months. The quarterly loss widened to $2.58 million from $1.99 million a year ago, driven by a 160% jump in R&D to $1.12 million as the recurrent C. difficile pilot trial got underway. More equity is the only apparent route to funding the Phase 3 program, and the company has already sold 2.6 million ELOC shares for $5.5 million this year while continuing to sell after the quarter closed. Because every raise at today's sub-$1 price adds shares faster than it adds cash, existing holders should expect continued dilution ahead of any partnership or financing.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACXP was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.92 to $7.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACXP - Latest Insights

ACXP
Sep 29, 2026, 8:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.966 info
Change: -$0.4461 (-32%) info
Market Cap: $5.337M info
ACXP
Aug 17, 2026, 8:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $0.966 info
Change: -$0.394 (-29%) info
Market Cap: $5.337M info
ACXP
Aug 14, 2026, 7:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.966 info
Change: -$0.664 (-41%) info
Market Cap: $5.337M info
ACXP
Aug 13, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $0.966 info
Change: -$0.5815 (-38%) info
Market Cap: $5.337M info
ACXP
Aug 03, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $0.966 info
Change: -$0.484 (-33%) info
Market Cap: $5.337M info